NCT01100736 - Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

January 31, 2010

Conditions

Pulmonary Arterial HypertensionVasodilationVasoconstriction

Interventions

DRUG

Bosentan

Bosentan 125mg tablets, orally, twice daily for 7 days

DRUG

Sitaxsentan

Sitaxsentan 100mg tablets, orally, once daily for 7 days

DRUG

Placebo

Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)

BIOLOGICAL

Endothelin-3

5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies

Trial Locations (1)

Clinical Research Centre, Western General Hospital, Edinburgh